The following study was recently activated for patient enrollment by the University of Illinois Cancer Center Clinical Trials Office.
Click the study link below to learn details regarding studies on clinicaltrials.gov. For more information or questions about a study, email cancertrials@uic.edu or call 312-355-5112.
Protocol Title: BA3182: An Open-label, Multicenter, Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Efficacy of BA3182, a Bispecific Epithelial Cell Adhesion Molecule (EpCAM)/CD3 Antibody, in Patients with Advanced Adenocarcinoma
PI: Lawrence Feldman, MD, part of the Cancer Center’s Translational Oncology Research Program
Sponsor: NovoCure Ltd.
Protocol Title: ALLO-647-201 : A Randomized, Open-label, Phase 2 Study Evaluating Lymphodepletion With Fludarabine, Cyclophosphamide, And ALLO-647, Vs. Fludarabine And Cyclophosphamide Alone, In Subjects With Relapsed/Refractory Large B-cell Lymphoma (LBCL) Receiving ALLO-501A Allogeneic Car T Cell Therapy
PI: Carlos Galvez, MD, UI Health Division of Hematology and Oncology
Sponsor: Allogene Therapeutics
